Balanced news tone
News Sentiment
IMNN sentiment intelligence
Imunon Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
80/100 classification confidence.
directly relevant articles
high-authority source matches
+5.8% over one week, +0.0% over four weeks, trend inactive, and below fair value.
OTC Markets Life Sciences Investor Forum: Stacy Lindborg, PhD, President, CEO, and Board Director, of Imunon with Zacks SCR’s David Bautz, PhD
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
OTC Markets Life Sciences Investor Forum: Stacy Lindborg, PhD, President, CEO, and Board Director, of Imunon with Zacks SCR’s David Bautz, PhD
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jul 2026 16:02
- Source
- Zacks Small Cap Research
Insider Sell: Susan Eylward Sells Shares of Imunon Inc (IMNN)
Susan Eylward, General Counsel and Corporate Secretary at Imunon Inc's subsidiary, sold 920 shares of IMNN on July 6, 2026. This transaction brings her total ownership down to 2,896 shares. Over the past year, there have been no insider buys and two insider sells at Imunon Inc, w
- Tone
- Negative 30/100
- Event
- Market update
- Published
- 07 Jul 2026 22:39
- Source
- GuruFocus
Imunon general counsel Susan Eylward sells $1,729 in company stock By Investing.com
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jul 2026 21:38
- Source
- Investing.com Nigeria
Imunon (IMNN) CFO Joshua Blacher files initial insider Form 3 ownership report
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jul 2026 21:01
- Source
- Stock Titan
Form 4 Imunon Inc For: 7 July By Investing.com
This article from Investing.com announces a Form 4 filing for Imunon Inc. on July 7, 2026. Form 4s typically report changes in beneficial ownership of company stock by insiders. The article notes Imunon Inc. (IMNN) is up 7.69%.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jul 2026 21:40
- Source
- Investing.com Nigeria
Imunon general counsel Susan Eylward sells $1,729 in company stock
Imunon's General Counsel, Susan Eylward, recently sold 920 shares of company stock for $1,729. This transaction followed her acquisition of the same number of shares, granted in lieu of salary, valued at $1,757. The stock is currently trading near its 52-week low, and company ana
- Tone
- Negative 40/100
- Event
- Deals and strategy
- Published
- 07 Jul 2026 21:39
- Source
- Investing.com
Imunon (IMNN) Executive Chairman receives 4,410-share stock grant as salary
Imunon, Inc. Executive Chairman Michael H. Tardugno received a grant of 4,410 shares of common stock at $1.91 per share, issued in lieu of cash for his base salary. This transaction increased his direct ownership to 64,396 shares, with an additional 4,622 shares held indirectly t
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 07 Jul 2026 20:40
- Source
- Stock Titan
Imunon (IMNN) CMO granted stock in lieu of part of salary
Imunon's Chief Medical Officer, Douglas Vincent Faller, received a grant of 1,308 shares of Common Stock on July 2, 2026, at $1.91 per share. This stock grant was provided in lieu of a portion of his base salary, making it a non-market compensation transaction. Following this tra
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jul 2026 20:40
- Source
- Stock Titan
Imunon (IMNN) General Counsel reports stock grant and 920-share sale
Imunon, Inc.'s General Counsel, Susan Eylward, reported receiving a stock grant of 920 shares at $1.91 each on July 2, 2026, as part of her base salary. She subsequently sold 920 shares in an open-market transaction at $1.88 each on July 6, 2026. After these transactions, Eylward
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jul 2026 20:39
- Source
- Stock Titan
Imunon (IMNN) CEO Stacy Lindborg receives stock grant instead of cash salary
Imunon, Inc.'s President and CEO, Stacy Lindborg, received a grant of 2,534 shares of common stock at $1.91 per share as part of her compensation, in lieu of a portion of her base salary. Following this transaction, Lindborg directly holds 76,722 shares and indirectly holds 778 s
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 07 Jul 2026 20:39
- Source
- Stock Titan
Imunon 1Q Loss/Shr 84c >IMNN
Imunon (IMNN) reported a first-quarter loss per share of 84 cents. This financial update provides key information regarding the company's recent performance.
- Tone
- Negative 24/100
- Event
- Market update
- Published
- 07 Jul 2026 01:13
- Source
- Moomoo
Imunon Names Josh Blacher Interim Chief Financial Officer
Imunon has appointed Josh Blacher as interim Chief Financial Officer, effective July 1, 2026, following the retirement of Jeffrey Church. Blacher, a finance executive from Danforth Health, Inc., will serve as the principal financial and accounting officer. The company's stock, IM
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 Jul 2026 05:09
- Source
- The Globe and Mail
IMNN - Imunon Inc Latest SEC Filings
This article provides the latest SEC filings information for Imunon Inc. (IMNN), alongside a comprehensive financial overview. It details key financial metrics, stock performance data, and insider/institutional ownership figures for the company.
- Tone
- Negative 41/100
- Event
- Market update
- Published
- 03 Jul 2026 15:09
- Source
- Finviz
Imunon (NASDAQ: IMNN) appoints Josh Blacher as interim CFO
Imunon, Inc. (NASDAQ: IMNN) has appointed Josh Blacher as its new interim Chief Financial Officer, effective July 1, 2026. This appointment follows the retirement of the previous interim CFO, Jeffrey Church, who will remain with the company as a consultant. Blacher will serve thr
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Jun 2026 20:39
- Source
- Stock Titan
Imunon CFO Jeffrey Church to Retire; Josh Blacher Named Interim CFO
Imunon has announced that its interim Chief Financial Officer, Jeffrey Church, will retire effective July 1, 2026. Josh Blacher has been named the interim CFO, taking over on the same date. Church will continue as a consultant for Imunon under an amended Consulting Agreement.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Jun 2026 20:39
- Source
- TradingView
Form 4 Imunon Inc For: 29 June By Investing.com
This article from Investing.com announces the Form 4 filing for Imunon Inc. on June 29th. It is a brief, factual notification regarding a regulatory filing for the company.
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 30 Jun 2026 14:12
- Source
- Investing.com Nigeria
Imunon (IMNN) CEO awarded 67,150 shares instead of cash bonus
Imunon, Inc. President and CEO Stacy Lindborg received a stock-based compensation grant of 67,150 shares at $1.72 per share, in lieu of 50% of her 2025 annual cash bonus. Following this transaction, Lindborg directly holds 74,188 shares and indirectly holds 778 shares through a 4
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 30 Jun 2026 01:14
- Source
- Stock Titan
Imunon (IMNN) counsel gets stock bonus, then sells 11,800 shares
Imunon's General Counsel, Susan Eylward, received 14,696 shares of common stock at $1.72 per share as part of her 2025 annual bonus. Shortly after, she sold 11,800 shares in an open-market transaction at a weighted average price of $1.752 per share, retaining 2,896 shares. This t
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Jun 2026 01:14
- Source
- Stock Titan
Insider Sell: Susan Eylward Sells 11,800 Shares of Imunon Inc (I
Susan Eylward, General Counsel and Corporate Secretary at a subsidiary of Imunon Inc, sold 11,800 shares of Imunon Inc (IMNN) on June 29, 2026. After this transaction, Eylward now holds 2,896 shares. Imunon Inc, a biotechnology company, has seen no insider buys but one insider se
- Tone
- Negative 37/100
- Event
- Market update
- Published
- 29 Jun 2026 23:14
- Source
- GuruFocus
Imunon (IMNN) chair takes half of 2025 cash bonus in stock grant
Imunon's Executive Chairman, Michael H. Tardugno, received 42,519 shares of common stock valued at $1.72 per share, in lieu of 50% of his 2025 annual cash bonus. This stock grant increases his direct holdings to 59,986 shares, plus an additional 4,622 shares held indirectly throu
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 29 Jun 2026 20:14
- Source
- Stock Titan
Imunon (IMNN) Chief Medical Officer granted 21,896 shares in lieu of 2025 cash bonus
Imunon, Inc.'s Chief Medical Officer, Douglas Vincent Faller, was granted 21,896 shares of common stock at $1.72 per share. This stock grant serves as 50% of his 2025 annual cash bonus, rather than a cash payment. Following this transaction, Faller directly owns 21,896 shares of
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 29 Jun 2026 20:14
- Source
- Stock Titan
Enterprise value to EBITDA forward of Imunon, Inc. – NASDAQ:IMNN
The article presents financial data for Imunon, Inc. (NASDAQ: IMNN), specifically focusing on its enterprise value to EBITDA forward metric. The content itself seems to be a display from a financial data platform, providing a snapshot of the company's financial overview. It does
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jun 2026 05:09
- Source
- TradingView
Price to earnings forward of Imunon, Inc. – DUS:CBO0
The article provides a financial data point for Imunon, Inc. (DUS:CBO0) on its price to earnings forward, indicating "No trades" at market close. The content is primarily a data page from TradingView, displaying financial overview information for the company.
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 28 Jun 2026 20:40
- Source
- TradingView
Price to sales forward of Imunon, Inc. – NASDAQ:IMNN
This article provides a brief snapshot of the "Price to sales forward" for Imunon, Inc. (NASDAQ: IMNN). It indicates that the market was closed with no trades at the time of publication. The content primarily shows the financial metric "Period Value Change Change %" for the compa
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Jun 2026 13:40
- Source
- TradingView
Price to book forward of Imunon, Inc. – NASDAQ:IMNN
This article provides a financial data point for Imunon, Inc. (NASDAQ: IMNN), specifically its "Price to book forward" metric. The content indicates that for this particular period, the value is not available, showing "No trades." It appears to be a stub or an entry from a financ
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Jun 2026 09:39
- Source
- TradingView
Imunon, Inc. Actuals & Estimates (FWB:CBO0)
This article provides key financial data and analyst insights for Imunon, Inc. (FWB:CBO0), including its stock ticker, price forecasts ranging from 8.61 EUR to 21.53 EUR, and historical price movements. It details recent earnings, revenue, and net income figures, noting that the
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 Jun 2026 16:10
- Source
- TradingView
Imunon, Inc. Actuals & Estimates (DUS:CBO0)
This article provides an overview of Imunon, Inc. (DUS: CBO0) stock, including financial actuals and estimates, analyst forecasts with price targets, and historical price data. It details recent earnings and revenue figures, upcoming earnings release dates, and confirms the compa
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 Jun 2026 05:39
- Source
- TradingView
Imunon, Inc. (IMNN) Presents at Life Sciences Virtual Investor Forum - Slideshow (NASDAQ:IMNN) 2026-06-26
Imunon, Inc. (IMNN) presented a slideshow at the Life Sciences Virtual Investor Forum. The article highlights that SA Transcripts published the slide deck and is responsible for developing all transcript-related projects for Seeking Alpha. This event provides investors with insig
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 04:10
- Source
- Seeking Alpha
A41CNR Forecast — Price Target — Prediction for 2027
This article provides a detailed forecast for Imunon, Inc. (A41CNR) stock, including price targets, analyst ratings, and historical performance data. It highlights that analysts have a max estimate of 21.53 EUR and a min estimate of 8.61 EUR for the stock, despite recent declines
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 25 Jun 2026 23:38
- Source
- TradingView